Efficacy of lansoprazole in the short- and long-term treatment of gastro-oesophageal reflux disease. A systematic overview

Clinical Drug Investigation

Volumn 14, Issue 6, 1997, Pages 450-456

  Manzionna, G ^a   Pace, F ^a   Porro, G Bianchi ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; RELAPSE;

EID: 0031453956     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199714060-00002     Document Type: Article

References (30)

1. Debonne JM, Berthezene P, Klotz F, et al. In: Giulì R, Tytgat G, DeMeester TR, et al., editors. The esophageal mucosa. Amsterdam: Elsevier, 1994: 56-62
2. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 11: 953-6
3. Tauris P. Upper gastrointestinal panendoscopy. Endoscopy 1978; 10: 231-9
4. Stoker DL, Williams JG, Leicester RG, et al. Oesophagitis: a five years review [abstract]. Gut 1988; 29: A1450
5. Howard PJ, Heading RC. Epidemiology of gastro-oesophageal reflux disease. World J Surg 1992; 16: 288-93
6. Timmer R, Breumelhof R, Jos H, et al. Recent advances in the pathophysiology of gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 1993; 5: 485-91
7. Mittal R, Balaban DH. The esophagogastric junction. N Engl J Med 1997; 336: 924-32
8. Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991; 101: 1149-58
9. Bell NJV, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992; 33: 118-24
10. Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276: 983-8
11. Corinaldesi R, Valentini M, Belaïche J, et al. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Aliment Pharmacol Ther 1995; 9: 667-71
12. Koop H, Schepp W, Dammann HG, et al. Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis: results of a German multicenter study. J Clin Gastroenterol 1995; 20: 192-5
13. Mössner J, Hölscher AH, Herz R, et al. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995; 9: 321-6
14. van Rensburg CJ, Honiball PJ, Grundling H de K, et al. Efficacy and tolerability of pantoprazole 40mg versus 80mg in patients with reflux oesophagitis. Aliment Pharmacol Ther 1996; 10: 397-401
15. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903-12
16. 2-receptor antagonists with lansoprazole, a new H+/K+-ATPase inhibitor: a controlled, double-blind study. Am J Gastroenterol 1993; 88: 1212-7
17. Robinson M, Sahba B, Avner D, et al. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther 1995; 9: 25-31
18. Bardhan KD, Hawkey CJ, Long RG, et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. Aliment Pharmacol Ther 1995; 9: 145-51
19. Umeda N, Miki K, Hoshino E. Lansoprazole versus famotidine in symptomatic reflux esophagitis: a randomized, multicenter study. J Clin Gastroenterol 1995; 20 Suppl. 1: S17-S23
20. Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole versus omeprazole in short term treatment of reflux oesophagitis. Scand J Gastroenterol 1993; 28: 224-8
21. Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 1996; 91: 1749-57
22. Mee AS, Rowley JL and the Lansoprazole Clinical Research Group. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996; 10: 757-63
23. Mulder CJ, Dekker W, Gerretsen M, on behalf of the Dutch Study Group. Lansoprazole 30mg versus omeprazole 40mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Eur J Gastroenterol Hepatol 1996; 8: 1101-6
24. 2-receptor antagonist therapy. Digest Dis Sci 1995; 40: 590-7
25. Dorsch E, Jones J, Padgett C, et al. Lansoprazole heals moderate to severe reflux esophagitis. Am J Gastroenterol 1991; 86: 1294
26. Robinson M, Lanza F, Avner D, et al. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. Ann Intern Med 1996; 124: 859-67
27. 2-RA therapy. Am J Gastroenterol 1996; 91: 1758-65
28. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48
29. SAS Institute Inc., SAS/STAT® Users Guide, Version 6, Fourth Edition, Volume 1, Cary, NC: SAS Institute Inc., 1989: 943
30. Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996; 10: 529-39